MX2019012749A - Metodos para tratar trastornos pediatricos. - Google Patents
Metodos para tratar trastornos pediatricos.Info
- Publication number
- MX2019012749A MX2019012749A MX2019012749A MX2019012749A MX2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A
- Authority
- MX
- Mexico
- Prior art keywords
- vedolizumab
- integrin
- beta
- alpha
- antibodies specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492031P | 2017-04-28 | 2017-04-28 | |
| PCT/US2018/029579 WO2018200818A2 (en) | 2017-04-28 | 2018-04-26 | Method of treating pediatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012749A true MX2019012749A (es) | 2020-02-03 |
Family
ID=62455814
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012749A MX2019012749A (es) | 2017-04-28 | 2018-04-26 | Metodos para tratar trastornos pediatricos. |
| MX2024003905A MX2024003905A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos. |
| MX2024012972A MX2024012972A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos |
| MX2024003906A MX2024003906A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003905A MX2024003905A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos. |
| MX2024012972A MX2024012972A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos |
| MX2024003906A MX2024003906A (es) | 2017-04-28 | 2019-10-24 | Vedolizumab para el tratamiento de pacientes pediatricos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200179486A1 (https=) |
| EP (1) | EP3615071A2 (https=) |
| JP (2) | JP2020517671A (https=) |
| KR (2) | KR20250134146A (https=) |
| CN (1) | CN110612120A (https=) |
| AR (1) | AR111491A1 (https=) |
| AU (2) | AU2018256840A1 (https=) |
| BR (1) | BR112019022268A2 (https=) |
| CA (1) | CA3061320A1 (https=) |
| IL (1) | IL270201B1 (https=) |
| MX (4) | MX2019012749A (https=) |
| TW (2) | TWI811216B (https=) |
| WO (1) | WO2018200818A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| EP3956358A4 (en) * | 2019-04-17 | 2023-01-25 | Millennium Pharmaceuticals, Inc. | COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR |
| US20220408780A1 (en) * | 2020-02-11 | 2022-12-29 | The E. Wolfson Medical Center | A method effective for treating ulcerative colitis |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025177055A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Combination therapy for treating inflammatory bowel disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| RS52213B (sr) | 2004-09-03 | 2012-10-31 | Genentech, Inc. | Humanizovani anti-beta7 antagonisti i njihove primene |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| DK3311834T3 (da) | 2011-05-02 | 2026-04-20 | Millennium Pharmaceuticals Inc | Formulering til anti-alfa4beta7-antistof |
| KR20170120601A (ko) * | 2015-02-26 | 2017-10-31 | 제넨테크, 인크. | 인테그린 베타7 길항제 및 크론병을 치료하는 방법 |
| BR112018068625A2 (pt) * | 2016-03-14 | 2019-07-30 | Millennium Pharm Inc | métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro |
-
2018
- 2018-04-26 BR BR112019022268-5A patent/BR112019022268A2/pt unknown
- 2018-04-26 WO PCT/US2018/029579 patent/WO2018200818A2/en not_active Ceased
- 2018-04-26 MX MX2019012749A patent/MX2019012749A/es unknown
- 2018-04-26 JP JP2019557637A patent/JP2020517671A/ja not_active Withdrawn
- 2018-04-26 US US16/608,895 patent/US20200179486A1/en active Pending
- 2018-04-26 KR KR1020257028168A patent/KR20250134146A/ko active Pending
- 2018-04-26 AU AU2018256840A patent/AU2018256840A1/en not_active Abandoned
- 2018-04-26 KR KR1020197030615A patent/KR20190141148A/ko not_active Ceased
- 2018-04-26 CN CN201880027856.4A patent/CN110612120A/zh active Pending
- 2018-04-26 EP EP18728257.9A patent/EP3615071A2/en active Pending
- 2018-04-26 CA CA3061320A patent/CA3061320A1/en active Pending
- 2018-04-27 AR ARP180101099A patent/AR111491A1/es not_active Application Discontinuation
- 2018-04-27 TW TW107114371A patent/TWI811216B/zh active
- 2018-04-27 TW TW112126603A patent/TW202342102A/zh unknown
-
2019
- 2019-10-24 MX MX2024003905A patent/MX2024003905A/es unknown
- 2019-10-24 MX MX2024012972A patent/MX2024012972A/es unknown
- 2019-10-24 MX MX2024003906A patent/MX2024003906A/es unknown
- 2019-10-27 IL IL270201A patent/IL270201B1/en unknown
-
2023
- 2023-05-10 JP JP2023077997A patent/JP2023113655A/ja active Pending
-
2025
- 2025-04-09 AU AU2025202525A patent/AU2025202525A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020517671A (ja) | 2020-06-18 |
| IL270201B1 (en) | 2026-01-01 |
| EP3615071A2 (en) | 2020-03-04 |
| JP2023113655A (ja) | 2023-08-16 |
| AR111491A1 (es) | 2019-07-17 |
| TW202342102A (zh) | 2023-11-01 |
| IL270201A (https=) | 2019-12-31 |
| MX2024003906A (es) | 2024-04-23 |
| MX2024012972A (es) | 2024-11-08 |
| WO2018200818A3 (en) | 2018-12-06 |
| AU2025202525A1 (en) | 2025-05-01 |
| CA3061320A1 (en) | 2018-11-01 |
| WO2018200818A2 (en) | 2018-11-01 |
| RU2019138312A3 (https=) | 2022-02-03 |
| BR112019022268A2 (pt) | 2020-05-19 |
| US20200179486A1 (en) | 2020-06-11 |
| RU2019138312A (ru) | 2021-05-28 |
| WO2018200818A9 (en) | 2019-01-17 |
| MX2024003905A (es) | 2024-04-23 |
| CN110612120A (zh) | 2019-12-24 |
| KR20250134146A (ko) | 2025-09-09 |
| AU2018256840A1 (en) | 2019-11-07 |
| TWI811216B (zh) | 2023-08-11 |
| KR20190141148A (ko) | 2019-12-23 |
| TW201842932A (zh) | 2018-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012749A (es) | Metodos para tratar trastornos pediatricos. | |
| DK3731772T3 (da) | Systems for the treatment of disease states and disorders | |
| LT3755356T (lt) | Kompozicijos, priemonės, sistemos, rinkiniai ir būdai odos ligos būklės gydymui | |
| SG11202107978RA (en) | Methods and system for the reconstruction of drug response and disease networks and uses thereof | |
| CL2017002237A1 (es) | Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
| EP3644996A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| SG11201911929XA (en) | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | |
| EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| EA201990778A1 (ru) | Анти-il-33 антитела и их применение | |
| MX380810B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| PL3774897T3 (pl) | Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi | |
| JOP20200231B1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| KR102354980B9 (ko) | 전안부 질환 진단 시스템 및 이를 이용한 진단 방법 | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| PT3405215T (pt) | Métodos para o tratamento da doença de danon e outros transtornos da autofagia | |
| EP3802539C0 (en) | NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3504204A4 (en) | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES | |
| MX386798B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| EA202190576A1 (ru) | Полиморфные соединения и их применение | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |